IDEAYA Biosciences, Inc.

IDEAYA Biosciences reported its third quarter 2026 financial results, with $1.15 billion in cash and equivalents. The company announced the completion of its NDA submission for darovasertib plus crizotinib in metastatic uveal melanoma and presented updated data for IDE849 in SCLC and NEC. R&D expenses increased to $121.6 million, contributing to a net loss of $125.7 million for the quarter. The company also announced the closure of the Phase 3 OptimUM-010 trial, expecting cost savings to be reallocated to other programs.

IDEAYA Biosciences reported its second quarter 2026 financial results, with a net loss of $112.5 million and collaboration revenue of $8.9 million. The company announced that its registrational OptimUM-02 trial for the darovasertib combination in metastatic uveal melanoma met its primary endpoint, with an NDA filing underway. IDEAYA ended the quarter with approximately $1.24 billion in cash, cash equivalents, and marketable securities, supported by $323.4 million in net proceeds from a recent public offering, extending its cash runway into 2030. The company also highlighted upcoming data presentations at ESMO and a new clinical collaboration with Roche for IDE892.

IDEAYA Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on June 16, 2026, where shareholders voted on three proposals. All three Class I directors, Yujiro S. Hata, M. Garret Hampton, Ph.D., and Catherine J. Mackey, Ph.D., were elected to serve until the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP as the independent auditor and approved the non-binding advisory vote on executive compensation. Following the meeting, the Board of Directors elected Yujiro S. Hata as Chairman of the Board and Terry Rosen, Ph.D., as the Lead Independent Director.

IDEAYA Biosciences, Inc. completed an equity offering, generating approximately $323.6 million in net proceeds. The offering included the sale of 7,222,225 shares of common stock, which incorporated the full exercise of the underwriters' option, and pre-funded warrants to purchase 5,555,576 shares. The transaction was executed under an underwriting agreement with J.P. Morgan Securities LLC, Jefferies LLC, TD Securities (USA) LLC, UBS Securities LLC, and Cantor Fitzgerald & Co.

IDEAYA Biosciences announced a clinical collaboration with F. Hoffmann-La Roche Ltd to evaluate IDE892, its investigational PRMT5 inhibitor, in combination with Roche's pan-RAS inhibitor RG6505. The study will focus on patients with pancreatic ductal adenocarcinoma that carry an MTAP deletion, a condition with no approved targeted treatment options. IDEAYA will sponsor the clinical trial, while Roche will supply RG6505, with both companies retaining commercial rights to their respective compounds.

IDEAYA Biosciences, Inc. presented complete data from its Phase 2/3 OptimUM-02 trial at the ASCO Annual Meeting, showcasing positive results for the darovasertib combination in first-line metastatic uveal melanoma. The trial met its primary endpoint, demonstrating a statistically significant improvement in median Progression-Free Survival (PFS) and Objective Response Rate (ORR) compared to the Investigator's Choice of Therapy (ICT) arm. While overall survival data is still maturing, an early trend suggests improvement. The combination therapy was generally well-tolerated.

IDEAYA Biosciences, Inc. filed a new automatic shelf registration statement on May 5, 2026, to replace its expiring prior registration statement. This action allows the company to continue its "at-the-market" (ATM) equity offering program. Under the existing Sales Agreement with Jefferies LLC, the company can offer and sell common stock with aggregate gross proceeds of up to $156.6 million, representing the remaining capacity available. The company had previously sold over $193.4 million in common stock under the prior registration statement.

IDEAYA Biosciences reported a net loss of $(98.5) million for Q1 2026, an increase from $(72.2) million in Q1 2025, with a net loss per share of $(1.11). The company generated its first collaboration revenue of $6.56 million during the quarter. As of March 31, 2026, IDEAYA held $972.9 million in cash, cash equivalents, and marketable securities, which management believes is sufficient to fund operations for at least 12 months.

IDEAYA Biosciences reported positive topline data from its Phase 2/3 OptimUM-02 registrational trial for darovasertib in combination with crizotinib, meeting its primary endpoint with a 58% reduction in disease progression risk. The company plans to submit a New Drug Application (NDA) in H2 2026 under the FDA's Real-Time Oncology Review program. IDEAYA also provided updates on other pipeline programs and reported Q1 2026 financial results, including $972.9 million in cash, cash equivalents, and marketable securities, with a cash runway into 2030.

IDEAYA Biosciences, Inc. announced its 2026 Annual Meeting of Stockholders will be held online on June 16, 2026, at 1:30 p.m. Pacific Time. Stockholders will vote on the election of three Class I directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and an advisory vote on named executive officer compensation. The Board recommends voting "FOR" all proposals.